COX-2, OTC Analgesics Safety Should Not Be "Blurred," NDMA Urges Cmte.
This article was originally published in The Tan Sheet
Executive Summary
FDA's Arthritis Advisory Committee should "avoid the blurring of the comparative safety of the COX-2 inhibitors with OTC analgesics" in its recommendation for Searle/Pfizer's Celebrex (celecoxib) precription analgesic agent, NDMA Senior VP William Soller, PhD, urged during the committee's Dec. 1 consider-ation of the drug for Rx status. NDMA said it was concerned the lay media could create confusion between Celebrex and OTC analgesics.